Sonoma Biotherapeutics

SOUTH SAN FRANCISCO, CA · Founded 2019 · CIK 0001877861 · Biotech · Private

Engineered regulatory T cell therapies for autoimmune and degenerative disease treatment

Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$265M
1 Form D · Aug 2021
62 months since last filing
Contracts
—
No federal contracts on record
Patents
40
0 granted · 40 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$264,999,940
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2117Renasant Bio—$55M
2118PIXIMUNE, INC.——
2119DFI Holding Inc.—$55M
2120Sonoma Biotherapeutics—$265M
2121ARVINAS, INC.—$129M
2122ARBOR EQUITY GROUP FUND I, LP—$500K
2123Indapta Therapeutics Inc.—$84M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Jeffrey BluestoneDirector · Executive Officer · Promoter
  • Toni HooverDirector
  • Richard KlausnerDirector
  • Terry RosenDirector
  • Maggie WilderotterDirector
  • Fan YuDirector

Patents

USPTO · 0 granted of 40
  • Citrullinated Antigen-specific Chimeric Antigen Receptors For Targeting Regulatory T Cells To Treat Hidradenitis Suppurativaapplication
  • Recombinant Cytokine Receptors And Methods Of Useapplication
  • Tethered INTERLEUKIN-2 Recombinant Receptors And Methods Of Useapplication
  • IL5RA Cell Surface Markersapplication
  • Methods Of Using LFA3-FC Fusion Proteinsapplication
  • Myelin Oligodendrocyte Glycoprotein-specific Chimeric Antigen Receptors And Methods Of Useapplication
  • Cells Comprising A Modified IRF4 Enhancer Elementapplication
  • Chimeric Antigen Receptors Containing An Antibody-inducible Domainapplication
  • Methods Of Using LFA3-FC Fusion Proteinsapplication
  • Chimeric Antigen Receptors With Atypical Transmembrane And/or Hinge Domainsapplication
  • Mog-specific Chimeric Antigen Receptors And Methods Of Useapplication
  • Methods Of Using LFA3-FC Fusions For Cell Therapyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.